2 April 2026
THE MERCHANTS TRUST PLC LEI: 5299008VJFXCUD2EG312 FINAL RESULTS FOR THE YEAR ENDED 31 JANUARY 2026 The following comprises extracts from the company’s Annual Report…
Murray Income Trust PLC (“the Company”) Legal Entity Identifier (LEI): 549300IRNFGVQIQHUI13 2 April 2026 Update on Transition of Portfolio Holdings The Board of Murray Income…
Imfinzi plus Imjudo combined with lenvatinib and TACE demonstrated a statistically significant and clinically meaningful improvement in progression-free survival in embolisation-eligible unresectable liver cancer in EMERALD-3 Phase III trial Imfinzi plus…
B.P. Marsh & Partners Plc(“B.P. Marsh”, “the Company” or “the Group”) Follow-on equity purchase in Pantheon Specialty Group Limited (“Pantheon”) B.P. Marsh and Partners…
31 March 2026
JAMES HALSTEAD PLC (“James Halstead or the “Company”) INTERIM RESULTS FOR THE HALF-YEAR ENDED 31 DECEMBER 2025 Solid H1 trading and despite challenging markets,…
Anpario plc (“Anpario”, “Group” or the “Company”) Final results Anpario plc (AIM: ANP), the independent manufacturer of natural and sustainable feed additives for animal…
Unilever PLC Response to Media Speculation Further to the announcement released on 20 March 2026, the Board of Unilever PLC (the “Company”) notes recent…
Efzimfotase alfa demonstrated positive results from global Phase III clinical programme in hypophosphatasia MULBERRY randomised, placebo-controlled trial showed efzimfotase alfa demonstrated statistically significant and clinically meaningful improvement…